

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medlive Technology Co., Ltd.

醫脈通科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2192)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CHANGE OF AUDITOR

Reference is made to the announcement of the Company dated 17 April 2026 in relation to the proposed change of auditor (the “**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board of the Company provides supplemental information in this announcement about the considerations of the Audit Committee with respect to section 2, particularly paragraph 2.2.4, of the guide issued by the Accounting and Financial Reporting Council (the “**AFRC**”) on 16 December 2021 (the “**Guide**”).

(a) Governance and leadership

The Audit Committee took note that Deloitte is one of the Big Four accounting firms. The Audit Committee obtained information on the governance structure of Deloitte and took note of Deloitte’s representation that it has established a quality assurance and control mechanism that spans across the engagement; by implementing globally aligned audit methodology, adopting a partner responsibility system, supplemented by the strength of independent quality review partner. The mechanism supports both group audit and component teams in executing audit and ensures audit quality.

The Audit Committee also noted that the Deloitte team serving the Company comprises an engagement partner, a client relationship and audit partner and an engagement quality review partner. Each of them has many years of audit experience. They are supported by a team of experienced auditors as well as specialist teams, most noticeably, the tax and business advisory team. Deloitte also represented to the Audit Committee that the quality of audit projects is the most important performance evaluation indicator for every partner involved in the engagement.

(b) Compliance with relevant ethical requirements

Deloitte has confirmed their compliance with the Code of Ethics for Professional Accountants published by the Hong Kong Institute of Certified Public Accountants, including the independence provision.

The Audit Committee also noted Deloitte’s global policy “Global Principles of Business Conduct”, which is available on its website and outlines Deloitte’s ethical commitments and expectations for all Deloitte staff. The key commitments set out in the Global Principles of Business Conduct include (i) conducting business with transparency, honesty and professionalism; (ii) training and supporting employees in ethical decision-making; (iii) establishing a culture of respect, diversity and inclusion; (iv) emphasis on delivering high quality services, maintaining professional standards and exercising due care and professional skepticism in their work.

Deloitte has conducted independence search prior to making a fee proposal to the Company and the Audit Committee noted that Deloitte has never provided any audit or non-audit services to the Company or its subsidiaries since its listing in 2021.

Based on the above, the Audit Committee concluded that Deloitte maintains good standards of integrity, objectivity, and independence.

(c) Industry knowledge and technical competence

The Audit Committee has taken into account the following credentials of Deloitte and the proposed audit engagement team to conclude that Deloitte has relevant industry experience to serve the Company:

- (i) Deloitte’s Life Science and Healthcare team has over 800 professionals.
- (ii) Deloitte has provided professional services to 25 out of 28 Fortune 500 life science and healthcare companies.

- (iii) Deloitte has provided audit services to 36 Hong Kong listed life science and healthcare companies.
- (iv) Client relationship and audit partner and majority of the core team members of the audit engagement team have relevant industry experience as well as extensive experience in providing audit services to listed companies.

(d) Engagement performance

The Audit Committee has obtained information on the audit methodology and audit strategy, including the scope, timing and direction of the audit to be conducted by Deloitte. Further, having considered the proposed audit engagement team structure, the Audit Committee is satisfied that Deloitte has adequate staff resources and capacity to perform a quality audit, having regard to the Group's business scale and the number of group entities.

(e) Communications and interaction with the Audit Committee

Deloitte has represented to the Audit Committee that their audit objectives are to ensure that they deliver audit services with a focus on business risks, internal control and compliance while fully integrating their professional experience and data-driven innovative auditing technologies in order to carry out the audit smoothly, in an orderly manner and of good quality.

Deloitte has committed to providing open and frequent communication with management and those charged with governance. The communication covers the timing of key milestones, the scope of the audit engagement and key issues and significant areas of the audit. Meetings between Deloitte and the Audit Committee will be conducted as and when key issues are identified as well as when communicating the overall audit plan and reporting audit findings and results.

(f) Monitoring process

The Audit Committee has reviewed public searches conducted on the websites of the relevant authorities, which did not identify any disciplinary actions concerning the relevant audit engagement partner and other key engagement team members of Deloitte.

The Audit Committee also noted that according to the AFRC annual inspection report for 2024–2025, Deloitte is among one of the Category A firms, whose engagements have been selected by the AFRC for inspection. None of Deloitte's engagements in 2024 called for significant improvements.

To the best knowledge of the Audit Committee, the Audit Committee is not aware of any behavior or activities from Deloitte that would threaten the integrity, objectivity and independence, or adversely affect its quality of audit, to the Company.

Based on the foregoing as well as the factors set forth in the Announcement, the Audit Committee is of the view that Deloitte is independent, competent and capable to be the external auditor of the Company.

The proposed appointment of Deloitte is subject to the approval of the Shareholders at the AGM to be held on 15 May 2026. A circular containing, among others, further details on the change of auditors and a notice of the AGM has been published on 21 April 2026.

By order of the Board
Medlive Technology Co., Ltd.
Tian Liping
Chairwoman and Chief Executive Officer

Hong Kong, 5 May 2026

As at the date of this announcement, the Board comprises Ms. Tian Liping, Mr. Tian Lixin, Mr. Tian Lijun and Ms. Zhou Xin as executive Directors; Mr. Eiji Tsuchiya and Mr. Kazutaka Kanairo as non-executive Directors; and Mr. Richard Yeh, Dr. Ma Jun and Ms. Wang Shan as independent non-executive Directors.